Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC..
Checkpoint inhibitors have improved the survival of patients with advanced tumors and show a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery, external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade 1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient experienced a major partial response and, following the resolution of diarrhea, she was re-challenged again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy shows macroscopically normal colonic mucosa inflammatory lesions.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
---|---|
Enthalten in: |
Oncoimmunology - 9(2020), 1 vom: 13. Mai, Seite 1760676 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
de Andrea, Carlos Eduardo [VerfasserIn] |
---|
Links: |
---|
Themen: |
colitis |
---|
Anmerkungen: |
Date Completed 06.07.2021 Date Revised 06.07.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/2162402X.2020.1760676 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315067616 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM315067616 | ||
003 | DE-627 | ||
005 | 20231226201913.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/2162402X.2020.1760676 |2 doi | |
028 | 5 | 2 | |a pubmed24n1050.xml |
035 | |a (DE-627)NLM315067616 | ||
035 | |a (NLM)32934876 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a de Andrea, Carlos Eduardo |e verfasserin |4 aut | |
245 | 1 | 0 | |a Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.07.2021 | ||
500 | |a Date Revised 06.07.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. | ||
520 | |a Checkpoint inhibitors have improved the survival of patients with advanced tumors and show a manageable toxicity profile. However, auto-immune colitis remains a relevant side effect, and combinations of anti-PD1/PDL1 and anti-CTLA-4 increase its incidence and severity. Here, we report the case of a 50-year-old patient diagnosed with stage IV cervical cancer that relapsed following radical surgery, external radiation/brachytherapy and standard chemotherapy. She was subsequently treated with Nivolumab and Ipilimumab combination and developed grade 2 colitis presenting a dissociation between endoscopic and pathological findings. At cycle 10 the patient reported grade 3 diarrhea and abdominal discomfort, without blood or mucus in the stools. Immunotherapy was withheld and a colonoscopy was performed, showing normal mucosa in the entire colon. Puzzlingly, histologic evaluation of randomly sampled mucosal biopsy of the distal colon showed an intense intraepithelial lymphocyte infiltration with crypt loss and some regenerating crypts with a few apoptotic bodies set in a chronically inflamed lamina propria, consistent with the microscopic diagnosis of colitis. Treatment with methylprednisolone 2 mg/kg was initiated which led to a decrease in the number of stools to grade 1. Additional investigations to exclude other causes of diarrhea rendered negative results. The patient experienced a major partial response and, following the resolution of diarrhea, she was re-challenged again with immunotherapy, with the reappearance of grade 2 diarrhea, leading to permanent immunotherapy interruption. We conclude and propose that performing random colonic biopsies should be considered in cases of immune checkpoint-associated unexplained diarrhea, even when colonoscopy shows macroscopically normal colonic mucosa inflammatory lesions | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Ipilimumab | |
650 | 4 | |a Nivolumab | |
650 | 4 | |a immune-related adverse event | |
650 | 4 | |a colitis | |
650 | 7 | |a Immune Checkpoint Inhibitors |2 NLM | |
650 | 7 | |a Ipilimumab |2 NLM | |
650 | 7 | |a Nivolumab |2 NLM | |
650 | 7 | |a 31YO63LBSN |2 NLM | |
700 | 1 | |a Perez-Gracia, Jose Luis |e verfasserin |4 aut | |
700 | 1 | |a Castanon, Eduardo |e verfasserin |4 aut | |
700 | 1 | |a Ponz-Sarvise, Mariano |e verfasserin |4 aut | |
700 | 1 | |a Echeveste, Jose I |e verfasserin |4 aut | |
700 | 1 | |a Melero, Ignacio |e verfasserin |4 aut | |
700 | 1 | |a Sanmamed, Miguel F |e verfasserin |4 aut | |
700 | 1 | |a Rodriguez-Ruiz, Maria Esperanza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Oncoimmunology |d 2012 |g 9(2020), 1 vom: 13. Mai, Seite 1760676 |w (DE-627)NLM218817029 |x 2162-402X |7 nnns |
773 | 1 | 8 | |g volume:9 |g year:2020 |g number:1 |g day:13 |g month:05 |g pages:1760676 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/2162402X.2020.1760676 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 9 |j 2020 |e 1 |b 13 |c 05 |h 1760676 |